BioXcel Therapeutics (BTAI) Short term Debt (2018 - 2026)
BioXcel Therapeutics' (BTAI) quarterly Short term Debt came in at $22.4 million in Q1 2026, up 299.98% year-on-year from $5.6 million in Q1 2025, and down 10.03% quarter-over-quarter from $24.9 million in Q4 2025.
BioXcel Therapeutics (BTAI) Short term Debt (2018 - 2026) Analysis & Trends
BioXcel Therapeutics' Short term Debt history runs 8 years deep, the most recent figure standing at $22.4 million for Q1 2026.
- On a quarterly basis, Short term Debt rose 299.98% year-over-year to $22.4 million in Q1 2026; TTM through Mar 2026 was $22.4 million, a 299.98% increase from a year earlier, with the FY2025 full-year figure at $24.9 million, changed N/A from the prior year.
- Short term Debt slipped to $22.4 million in Q1 2026 per BTAI's latest filing, from $24.9 million in the prior quarter.
- Across five years, Short term Debt topped out at $24.9 million in Q4 2025 and bottomed at $56000.0 in Q1 2022.
- The 4-year median for Short term Debt is $792000.0 (2023), against an average of $7.0 million.
- Across the five-year window, Short term Debt jumped 74.68% in 2022 and jumped 578.57% in 2023, its largest moves.
- Year by year, Short term Debt stood at $422000.0 in 2022, then soared by 72.99% to $730000.0 in 2023, then soared by 3315.21% to $24.9 million in 2025, then decreased by 10.03% to $22.4 million in 2026.
- Per Business Quant, the three latest BTAI Short term Debt figures stand at $22.4 million (Q1 2026), $24.9 million (Q4 2025), and $16.8 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | BioXcel Therapeutics | 10.62 Mn | 10.62 Mn | -77,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.43 Mn |
| Dec 31, 2025 | 24.93 Mn |
| Sep 30, 2025 | 16.82 Mn |
| Jun 30, 2025 | 11.22 Mn |
| Mar 31, 2025 | 5.61 Mn |
| Sep 30, 2023 | 730,000.00 |
| Jun 30, 2023 | 854,000.00 |
| Mar 31, 2023 | 380,000.00 |
| Dec 31, 2022 | 422,000.00 |
| Sep 30, 2022 | 269,000.00 |
| Jun 30, 2022 | 296,000.00 |
| Mar 31, 2022 | 56,000.00 |
| Dec 31, 2021 | 204,000.00 |
| Sep 30, 2021 | 154,000.00 |
| Jun 30, 2021 | 106,000.00 |
| Dec 31, 2020 | 157,000.00 |
| Sep 30, 2020 | 208,000.00 |
| Dec 31, 2019 | 64,000.00 |
| Mar 31, 2018 | 13,000.00 |